Discovery and characterization of olokizumab A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling

被引：67

作者：

Shaw, Stevan ^{[1
]}

Bourne, Tim ^{[1
]}

Meier, Chris ^{[1
]}

Carrington, Bruce ^{[1
]}

Gelinas, Rich ^{[2
]}

Henry, Alistair ^{[1
]}

Popplewell, Andrew ^{[1
]}

Adams, Ralph ^{[1
]}

Baker, Terry ^{[1
]}

Rapecki, Steve ^{[1
]}

Marshall, Diane ^{[1
]}

Moore, Adrian ^{[1
]}

Neale, Helen ^{[1
]}

Lawson, Alastair ^{[1
]}

机构：

[1] UCB Pharma, Slough, Berks, England

[2] Inst Syst Biol, Seattle, WA USA

来源：

MABS | 2014年 / 6卷 / 03期

关键词：

interleukin; 6; IL-6; antibody; site; 3; gp130; olokizumab; neutralization; structure; CONFORMATIONAL-CHANGE; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; PHASE-II; BLOCKADE; DISEASE; IL-6; TOCILIZUMAB; COMBINATION;

D O I：

10.4161/mabs.28612

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, cell biology and primate pharmacology demonstrate the therapeutic potential of targeting IL-6 at Site 3, blocking the interaction with the signaling co-receptor gp130.

引用

页码：773 / 781

页数：9

共 55 条

[11] MolProbity: all-atom structure validation for macromolecular crystallography
Chen, Vincent B.
Arendall, W. Bryan, III
Headd, Jeffrey J.
Keedy, Daniel A.
Immormino, Robert M.
Kapral, Gary J.
Murray, Laura W.
Richardson, Jane S.
Richardson, David C.
[J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2010, 66 : 12 - 21
[12] Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, HS
Mason, K
Ramyar, KX
Stanley, AM
Gabelli, SB
Denney, DW
Leahy, DJ
[J]. NATURE, 2003, 421 (6924) : 756 - 760
[13] Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
Dayer, Jean-Michel
Choy, Ernest
[J]. RHEUMATOLOGY, 2010, 49 (01) : 15 - 24
[14] DeLano W.L., 2002, The PyMOL molecular graphics system
[15] RANK is essential for osteoclast and lymph node development
Dougall, WC
Glaccum, M
Charrier, K
Rohrbach, K
Brasel, K
De Smedt, T
Daro, E
Smith, J
Tometsko, ME
Maliszewski, CR
Armstrong, A
Shen, V
Bain, S
Cosman, D
Anderson, D
Morrissey, PJ
Peschon, JJ
Schuh, J
[J]. GENES & DEVELOPMENT, 1999, 13 (18) : 2412 - 2424
[16] Coot:: model-building tools for molecular graphics
Emsley, P
Cowtan, K
[J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2004, 60 : 2126 - 2132
[17] Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
Fizazi, K.
De Bono, J. S.
Flechon, A.
Heidenreich, A.
Voog, E.
Davis, N. B.
Qi, Ming
Bandekar, R.
Vermeulen, J. T.
Cornfeld, M.
Hudes, G. R.
[J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (01) : 85 - 93
[18] Fleischmann R, 2012, ARTHRITIS RHEUMATISM, P64
[19] EVIDENCE FOR CONTINUOUS STIMULATION OF INTERLEUKIN-6 PRODUCTION IN CROHNS-DISEASE
GROSS, V
ANDUS, T
CAESAR, I
ROTH, M
SCHOLMERICH, J
[J]. GASTROENTEROLOGY, 1992, 102 (02) : 514 - 519
[20] IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17
Hashizume, M.
Hayakawa, N.
Mihara, M.
[J]. RHEUMATOLOGY, 2008, 47 (11) : 1635 - 1640

← 1 2 3 4 5 6 →